TRAIL, Fas Ligand, TNF and TLR3 in Cancer (Resistance to Targeted Anti-Cancer Therapeutics) 1st ed

TRAIL, Fas Ligand, TNF and TLR3 in Cancer (Resistance to Targeted Anti-Cancer Therapeutics) 1st ed

$19

by Olivier Micheau

Category:

    TRAIL, Fas Ligand, TNF and TLR3 in Cancer (Resistance to Targeted Anti-Cancer Therapeutics) 1st ed

    by Olivier Micheau (Editor)

    This volume provides the current understanding of death receptor’s/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy. But an increasing body of evidence suggests that some of these receptors may also contribute to tumorigenesis, or that new players such as TLR3 may be targeted for cancer therapy due to their ability to behave like death receptors.

     

    Product details

    • Series: Resistance to Targeted Anti-Cancer Therapeutics (Book 12)
    • Hardcover: 317 pages
    • Publisher: Springer; 1st ed. 2017 edition (July 4, 2017)
    • Language: English
    Tags:

Related Products